Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs – News-Medical.net
|
Stem Cell Therapeutics Nabs Sirpa Protein-Targeting Mabs
News-Medical.net Biopharmaceutical immuno-oncology company Stem Cell Therapeutics (SCT) has entered an agreement to exclusively license worldwide rights to a panel of fully human monoclonal antibodies targeting the SIRPa protein (CD172a). This technology was … Stem Cell Therapeutics Strengthens CD47 Franchise With Acquistion of …Stockhouse |
